Cervical Cancer Screening Market Size, Share & Industry Analysis, By Test Type (Pap Test, HPV test, Visual Inspection with Acetic Acid (VIA) Test, Others), By Age Group (20-40 Years, Above 40 Years), By End Users (Hospitals, Specialty Clinics, Diagnostic Centers) and Regional Forecast, 2024-2032

Cervical cancer is a type of cancer caused due to the uncontrolled proliferation of the cells. The risk of cervical cancer is associated with human papillomavirus (HPV) infection in the cervix. As per the WHO statistics, cervical cancer is ranked fourth among the most frequent cancer in women with approximately 570,000 new cases in 2018. This rising prevalence of cervical cancer has increased the need for cervical cancer screening tests among women. Cervical cancer screening is an important part of a woman’s routine health and can help in the prevention of cervical cancer. Broadly, the cervical cancer screening test is of two types- Pap test and HPV testing. In the Pap test, cells from the cervix are isolated, stained and examined for abnormalities. In HPV test cells collected from the cervix are examined for the presence of infection from HPV. Many women are now opting for a cervical cancer screening test owing to the increasing awareness among them. The government is also playing a crucial role by organizing free medical camps, health reimbursement and awareness programs. This has also resulted in an increase in the number of cancer diagnostic centers and service providers, which is expected to favor the expansion of the cervical cancer screening industry.

Key Market Driver -

Increase in prevalence of cervical cancer

Key Market Restraint -

Limited access to cervical cancer screening test

Global cervical cancer screening market growth is being driven by the increase in the prevalence of cervical cancer, the rise in female geriatric population, and advancements in the cervical cancer screening. Furthermore, favorable health reimbursement, active government support, and rising concern for women’s health are also a few of the major factors that are expected to augment the cervical cancer screening market. According to GLOBOCAN 2018, the global burden of cervical cancer is estimated to rise from 569,847 cases to 642,421 cases by the year 2025, which is anticipated to fuel the cervical cancer screening market.

However, the lack of skilled professionals and limited access to cervical cancer screening tests are the major factors that can hamper the growth of the global cervical cancer screening market.

Key Players Covered:

The major companies covered in the global cervical cancer screening market report include Abbott, Advaxis, Inc., Pfizer Inc., Quest Diagnostics Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Meyrs Squibb Company, TruScreen, and other players.

As per the current cervical cancer screening market trends, Pap test among the test type is anticipated to register a higher market share in the global cervical cancer screening market owing to increased government funding and insurance coverage. For example, Medicare, a government-aided health insurance program in the United States, provides coverage for one PAP test once every 24 months and once every 12 months.

Key Insights:

• Prevalence of cervical cancer for key countries


• Regulatory scenarios for key countries


• Reimbursement scenario for key countries


• Key mergers and acquisitions

Regional Analysis:

The global cervical cancer screening market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the cervical cancer screening market during the forecast period owing to the high prevalence of cervical cancer and increased HPV infection rates. According to the American Cancer Society estimates, 13,240 new cases of cervical cancer will be diagnosed in the United States in 2018.

To gain extensive insights into the market, Request for Customization

In Europe, the cervical cancer screening market is anticipated to expand owing to the favorable health reimbursement and rapid adoption of advanced cervical cancer screening procedures. Asia Pacific is projected to witness remarkable growth during the forecast period owing to the increase in the number of cancer institutes, the presence of high geriatric population, and increased investment in public health. The cervical cancer screening market in Latin America and Middle East & Africa is estimated to expand owing to the rising concern on women’s health and increasing awareness about cervical cancer.

Segmentation

Cervical Cancer Screening Industry Developments

• In January 2019, MobileODT collaborated with Apollo Hospitals and Genworks for the launch of first pilot use of Artificial Intelligence for cervical cancer screening in India.


• In March 2019, Public Health England launched its national marketing campaign with the aim to generate awareness and encourage women to undergo cervical cancer screening.


• In November 2018, QIAGEN launched QIAscreen HPV PCR Test that can detect 15 genotypes of cervical cancer causing human papillomavirus (HPV).